Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of LY3002813 (Donanemab) in Early Symptomatic Alzheimer's Disease
NCT03367403Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2017
- Primary completion
- Dec 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of donanemab in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Dec 2017; status: completed.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03367403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03367403.